This page discusses misconceptions about liver hexokinase (hexokinase D, often called glucokinase) and is one of a series that discuss common errors in current textbooks of biochemistry.
All of the pages in this series are in urgent need of updating.
The biochemical principles have not changed, of course, but textbooks have: some of
those that were current when I first prepared these pages in 2000 have appeared in new editions, and
others have ceased to be widely used. New books have appeared that are not discussed. Unfortunately
I do not have easy access to any of the commonly used textbooks, as I work in a research (not teaching)
environment in a country where English is not the everyday working language. I could buy them, of course,
but that would represent rather a large investment for the sake of a few web pages.
Accordingly
I should be grateful if someone would collaborate with me in the revision. If you have access to
all of the textbooks published in English in the past ten years (say 1996 or later)
that are commonly used for teaching biochemistry, and if you would like to
help, please contact me at acornish@ibsm.cnrs-mrs.fr.
The basic error is to be misled into thinking that the misnomer glucokinase gives a correct impression of the specificity of liver hexokinase, as in the following statement from p. 298 of Campbell:
In some organisms there is a glucokinase, an enzyme that specifically phosphorylates glucose
However, some authors add to the confusion with a whole series of incorrect statements, as on p. 576 of Garrett and Grisham:
Liver contains an enzyme called glucokinase, which also carries out the [hexokinase] reaction, but is highly specific for D-glucose, has a much higher Km for glucose (approximately 10.0 mM), and is not product-inhibited... (Patients with diabetes mellitus produce insufficient insulin. They have low levels of glucokinase, cannot tolerate high levels of blood glucose, and produce little liver glycogen.)
We are mainly concerned here with the first sentence, though the parenthesis quoted after it also contains some less frequently encountered confusion that is mentioned below. The first sentence makes three points, all of them wrong:
The sentence about diabetes mellitus confuses different types of this disease: the type in which liver
hexokinase has been implicated is maturity-onset diabetes of the young (often called MODY), which in adulthood leads to
symptoms of non-insulin-dependent diabetes mellitus (NIDDM;
, type II diabetes mellitus),
whereas the type normally treated by administration of insulin is insulin-dependent diabetes mellitus (IDDM;
, type I diabetes mellitus).
The following passage from Stryer (p. 495) is not a lot better:
Liver possesses glucokinase, a specialized isoform of hexokinase that is not inhibited by glucose 6-phosphate. Glucokinase phosphorylates glucose only when it is abundant because it has a much higher KM for glucose than does hexokinase (5 mM, compared with 0.1 mM). the role of glucokinase is to provide glucose 6-phosphate for the synthesis of glycogen, a storage form of glucose (p. 586). The high KM of glucokinase in the liver gives brain and muscle first call on glucose when its supply is limited.
The following passage from Zubay (p. 326) is less objectionable, but repeats the error relating to Km, and although it doesn't explicitly state that the name glucokinase refers to different specificity from hexokinase it certainly leaves that impression. Moreover, the remarks about the physiological function are so vague that one is left wondering why the enzyme is mentioned at all:
The liver contains another enzyme, named glucokinase, that catalyzes the same reaction as hexokinase. Its Michaelis constant (about 10 mM) is 1,000 times as large as that of hexokinase; thus glucokinase can function only when the concentration of glucose is relatively high. Probably this enzyme is active only when blood glucose is high and the liver is taking up glucose for conversion to glycogen.
The following passage from McKee and McKee (p. 181) illustrates that it is quite possible for
authors to be scientifically correct if they try. Although the statement that hexokinase D is not inhibited by glucose 6-phosphate might be
objectionable in a mechanistic context, the reference here is clearly to the physiological role. Although the account does
not specifically mention that hexokinase D does not follow Michaelis–Menten kinetics, the use of the term half-saturated
avoids giving the
wrong impression that it does:
Hexokinase D, an isoenzyme found only in liver, has specific properties. The other hexokinases have high affinities for glucose relative to its concentration in blood (i.e., they are half-saturated at concentrations of less than 0.1 mM). (Blood glucose levels are approximately 4–5 mM.) In addition, hexokinase D requires much higher glucose concentrations for optimal activity (about 10 mM). Because hexokinase D activity is not inhibited by glucose 6-phosphate, this enzyme contributes significantly to the liver’s capacity to regulate blood glucose.
Likewise the following statement from Mathews, van Holde and Ahern (p. 452) is largely correct apart from the misleading mention of a very high KM:
Vertebrate liver contains a distinctive form of hexokinase, characterized by a very high KM for glucose (about 10 mM), a sigmoidal concentration dependence on glucose, and an insensitivity to inhibition by glucose-6-phosphate. This special hexokinase allows the liver to adjust its rate of glucose utilization in response to variations in blood glucose levels. In fact, as discussed in Chapters 16 and 23, a major role of liver is to regulate blood glucose levels, and this enzyme represents one of the principal mechanisms by which it does so. This form of hexokinase is often called glucokinase, although its substrate specificity is identical to that of hexokinase.
This error is perhaps less fundamental than most of the others here, but it is common in modern textbooks and raises the question of whether textbook authors ever read the primary literature or just content themselves with paraphrasing one another. This particular one happens to be close to my past interests, but there are probably others just as common that I don't notice.
The main reason why it matters is that it clearly confuses authors of reviews and research articles about the evolution of enzyme properties and structures, who speculate about meaningless questions of why hexokinase specificity evolved independently in the vertebrate and other lines. Note that the name glucokinase and the EC number 2.7.1.2 are quite properly applied to the genuinely specific enzymes that occur in bacteria and some other organisms. The IUBMB compilation Enzyme Nomenclature allows (misguidedly, in my view) the name but not the number to be applied to liver hexokinase.
M. L. Cárdenas (1995)
Glucokinase
: its regulation and role in liver metabolism
R. G. Landes, Austin, Texas
M. L. Cárdenas, A. Cornish-Bowden and T. Ureta (1998)
Evolution and Regulatory Role of the Hexokinases
,
Biochim. Biophys. Acta 1401, 242-264
| Abeles, Frey and Jencks | Barely mentioned | pp. 586–587 | |
| Campbell | Short incorrect statement of specificity | p. 346 | |
| Garrett and Grisham | All the usual misconceptions, compounded by confusion about diabetes mellitus | p. 576 | |
| Horton et al. | Michaelis constant mentioned on p. 181, but sigmoid curve illustrated on p. 344; otherwise correct | p. 181 | |
| Lehninger, Nelson and Cox | Mainly accurate, but incorrect statement of specificity on p. 406 | pp. 406, 432–433 | |
| McKee and McKee | Correct presentation without errors | p. 181 | |
| Mathews, van Holde and Ahern | Largely correct | p. 452 | |
| Stryer | Most of the usual misconceptions | p. 495 | |
| Voet and Voet | Correct and largely complete account | p. 505–506 | |
| Zubay | Specificity error implied; Michaelis constant error explicit | p. 326 |
Other common errors in textbooks